Clinical Trial Update: A 24-week Prospective, Open-label, Multicenter, Single-arm rPMS Study in Real-world Setting for Atectura®

View source ↗

Summary

An ongoing 24-week prospective, open-label, multicenter, single-arm real-world study of Atectura for asthma, sponsored by Novartis Pharmaceuticals; the trial is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Atectura

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Asthma | Status: RECRUITING